1.34
+0.01(+0.75%)
Currency In USD
| Previous Close | 1.33 |
| Open | 1.34 |
| Day High | 1.35 |
| Day Low | 1.33 |
| 52-Week High | 2.04 |
| 52-Week Low | 1.19 |
| Volume | 2.31M |
| Average Volume | 3.48M |
| Market Cap | 1.06B |
| PE | -22.33 |
| EPS | -0.06 |
| Moving Average 50 Days | 1.33 |
| Moving Average 200 Days | 1.51 |
| Change | 0.01 |
If you invested $1000 in OPKO Health, Inc. (OPK) 10 years ago, it would be worth $79.67 as of July 03, 2025 at a share price of $1.34. Whereas If you bought $1000 worth of OPKO Health, Inc. (OPK) shares 5 years ago, it would be worth $356.38 as of July 03, 2025 at a share price of $1.34.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
OPKO Health to Participate in the 3rd Annual Piper Sandler Virtual Obesity Symposium
GlobeNewswire Inc.
Jun 25, 2025 3:00 PM GMT
MIAMI, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) today announced its participation in the 3rd Annual Piper Sandler Obesity Symposium being held virtually on June 26, 2025. Management will be participating in a fireside discu
OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting
GlobeNewswire Inc.
Jun 25, 2025 12:00 PM GMT
MIAMI and JERUSALEM, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX) (“Entera”) today announced that new pharmacologic and pharmacokinetic in vivo data for investigational oral OPK-88006 tablet t
OPKO Health’s ModeX Therapeutics Announces Formation of Scientific Advisory Board with Leaders at the Forefront of Immunology and Oncology Drug Development
GlobeNewswire Inc.
Jun 09, 2025 12:00 PM GMT
Will provide expertise across ModeX’s portfolio of next generation multispecific antibodies for complex diseases involving the immune system, including cancer ModeX’s promising immunology pipeline includes first-in class drugs with two assets in ongo